Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine.

AIDS research and human retroviruses - 20 Sept 2000

Pilon A A, Marchand C, Kavlick M F, Bajaj K, Owen J, Mitsuya H, Pommier Y

Abstract excerpt

Metabolites of AZT can inhibit HIV-1 integrase in vitro (Mazumder A, et al., Proc Natl Acad Sci USA 1994;91:5771-5775). To determine if long-term dideoxynucleoside therapy can lead to the emergence of HIV-1 AZT-resistant variants containing mutations in the integrase, we have sequenced the proviral DNA encoding the HIV-1 integrase of nine HIV-1-infected patients at different time points during treatment. Four of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Microbial

Share to HIV Infections

Share to HIV Integrase

Share to Proviruses

Share to Reverse Transcriptase Inhibitors

Share to Zidovudine

Source

Identifiers

PMID: 11018861
DOI: 10.1089/08892220050140964

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine.PMID 11018861Read ↗

The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1.Semantic proximity Read ↗

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.Semantic proximity Read ↗

In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.Semantic proximity Read ↗

Long-term persistence of AZT-resistance mutations in the plasma HIV-1 of patients removed from AZT therapy.Semantic proximity Read ↗

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.Semantic proximity Read ↗

Structures of reverse transcriptase pre- and post-excision complexes shed new light on HIV-1 AZT resistance.Semantic proximity Read ↗

Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse TranscriptaseSemantic proximity Read ↗

Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.Semantic proximity Read ↗

Natural resistance of human immunodeficiency virus type 2 to zidovudine.Semantic proximity Read ↗

In vivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy.Semantic proximity Read ↗

High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.Semantic proximity Read ↗

Predominance of codon 215 mutation in reverse transcriptase-coding region of 3'-azido-3'-deoxythymidine (AZT)-resistant HIV-1 isolates after long-term AZT therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.